Global News

GlaxoSmithKline PLC (NYSE:GSK) Shares Bought by Delta Asset Management LLC TN

GlaxoSmithKline PLC (NYSE:GSK) Shares Bought by Delta Asset Management LLC TN

Barclays Capital maintained GlaxoSmithKline plc (LON:GSK) rating on Monday, August 3.

Other hedge funds have also recently modified their holdings of the company. Beaufort Securities maintained the shares of GSK in report on Thursday, April 27 with "Buy" rating. Also, insider Patrick Vallance bought 861 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 14th.

10/25/2016 - GlaxoSmithKline PLC had its "neutral" rating reiterated by analysts at JP Morgan. Finally, Exane BNP Paribas raised GlaxoSmithKline PLC from an "underperform" rating to a "neutral" rating in a report on Wednesday, April 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company.

Shares of GlaxoSmithKline plc (LON GSK) traded down 0.94% during mid-day trading on Wednesday, reaching GBX 1531.00.

About 4.82M shares traded. GBX 1677.50's average target is 10.14% above currents GBX 1523 stock price.

GlaxoSmithKline PLC has PE ratio of 44.90 with a one year low of 1,446.50GBX and a one year high of 1,745.56GBX and has a market capitalization of 0 GBX.

Investec Securities now has a GBX 1800.00 target price on the 74.91B GBP market cap company or 15.13 % upside potential.

Anthony Scaramucci Vs. Reince Priebus: White House Drama Escalates
The interview naturally sent the internet into a DEFCON 1 meltdown, as Twitter eagerly awaited The Mooch's response. The financial disclosure forms were not leaked but were publicly accessible upon request, Politico noted .

The share price of GlaxoSmithKline (LON:GSK) was down -2.55% during the last session with a day high of 1606.00. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.62. Net profit margin of the company was recorded at 5.8 percent, operating profit margin was 12.4 percent, whereas gross profit margin stands at 68.4 percent.

GlaxoSmithKline plc (GSK) has 2.44 Billion shares outstanding and 2.44 Billion shares were floated in market.

ILLEGAL ACTIVITY NOTICE: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of USA and global trademark and copyright legislation. The original version of this article can be read at

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a dividend yield of 1.23%. Bronfman E.L. Rothschild L.P. increased its position in GlaxoSmithKline PLC by 45.4% in the first quarter.

According to Zacks, analysts expect that GlaxoSmithKline PLC will report full-year sales of $9.52 billion for the current year, with estimates ranging from $38.85 billion to $39.63 billion.

Several equities analysts have weighed in on GSK shares. FMR LLC boosted its stake in GlaxoSmithKline PLC by 11.7% in the first quarter. The company's stock had a trading volume of 1,863,654 shares. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company's stock valued at $124,000 after buying an additional 400 shares during the period. Renaissance Technologies LLC boosted its stake in GlaxoSmithKline PLC by 42.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company's stock worth $996,452,000 after buying an additional 2,482,009 shares during the period. Heritage Trust Co acquired a new position in GlaxoSmithKline PLC during the first quarter valued at $123,000. Proficio Capital Partners LLC increased its position in GlaxoSmithKline PLC by 233.0% in the first quarter. Juncture Wealth Strategies LLC now owns 6,700 shares of the pharmaceutical company's stock valued at $289,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 8.98% of the company's stock.

The company has just set a target price of GBX 1885.00 on Glaxosmithkline (LON:GSK) shares. The corporation operates through around three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.